R-Biopharm AG: Flu tests from R-Biopharm also detect new virus variants
25.11.2022 11:23:27 CET | news aktuell GmbH | Press release
Darmstadt, November 25, 2022: The flu season has begun and different virus variants are also circulating in Germany. With the flu tests from biotechnology company R-Biopharm, patients quickly have certainty: Its RIDA®GENE Flu assays also reliably detect the two novel variants. The company made the announcement with regard to influenza A H1N1pdm09, which is circulating primarily in the United Kingdom, and the H3N2 subtype, which was rampant in Denmark in the spring and is currently dominating influenza activity in Germany.
"Mutations in the target gene (MP gene) can affect the diagnostic performance of influenza screening assays, producing false-negative test results," explains Dr. Andreas Simons, Head of Product Management at R-Biopharm. " Alignments of the detection systems we used with the described sequences of the two novel virus variants showed no mismatches. Their reliable detection is not affected by the described mutations."
This means laboratories can continue to reliably confirm or rule out influenza infections using R-Biopharm's RIDA®GENE (PG0505, PG0545, PG6825) assays. The tests are multiplex real-time RT-PCR for the direct qualitative detection of influenza viruses.
About R-Biopharm
R-Biopharm AG, located in Darmstadt, is one of Germany's leading biotechnology companies. Founded in 1988, the company is family-run in the second generation and considers itself as a pioneer for health and quality of life. Its aspiration: to provide the highest possible precision, safety, clarity and certainty in prevention, therapy and healing. To this end, R-Biopharm develops technologies, products and solutions for Clinical Diagnostics, Nutrition Care and Food and Feed Analytics – and does so in internationally recognized top quality. R-Biopharm is the world market leader for test systems in the field of allergen analysis.
R-Biopharm unites research, development and sales under one roof in order to respond to ever new challenges with agile processes and to accompany the steadily growing world population into a new health era. The company is represented in more than 120 countries – through 29 subsidiaries and 120 distributors. It employs around 1,400 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the "Sustainability Award" for sustainable and profitable growth.
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/de/kontakt/presse
https://r-biopharm.com/de/news-presse/download-galerie
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt
Phone: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
Images
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Slovak outlet Denník N republishes numerous false allegations about Alisher Usmanov that courts have already held to be unlawful13.3.2026 08:48:33 CET | Press release
(Hamburg, Germany - 12 March 2026) On 11 March 2026, the Slovak news outlet Denník N published an article concerning the alleged efforts of the Slovak government to secure the removal of two Russian nationals from the EU sanctions list. The article contained an extensive passage concerning our client, Mr Alisher Burkhanovich Usmanov. By letter dated 12 March 2026, Denník N was requested, in order to avoid court proceedings, to provide a cease-and-desist undertaking backed by a contractual penalty. “The article was published on the eve of the European Commission’s decision on the extension of the sanctions. It reads as if its authors had taken particular care to assemble, in a single piece, every factual allegation that courts have previously found to be unlawful,” said Mr Usmanov’s lawyer, Joachim Nikolaus Steinhöfel. The article contained a dozen such statements about Alisher Usmanov, even though these very allegations have for years been prohibited, retracted, deleted or corrected in
Ship parades, evening shows and partner region Liverpool The 837th HAMBURG PORT ANNIVERSARY with a top programme11.3.2026 14:02:16 CET | Press release
(Hamburg, 11 March 2026) From 8 to 10 May 2026, Hamburg is celebrating its 837th HAMBURG PORT ANNIVERSARY. The programme includes traditional highlights such as the arrival and departure parades and the unique tugboat ballet, as well as several evening shows and the fascinating fireworks display. The programme will be supplemented by new events on the water and on land. The Big Arrival Parade on Friday, 8 May, at 1:30 p.m. marks the start of the festivities and is always an unforgettable experience: more than 100 impressive ships sail up the Elbe right before the eyes of the spectators. The majestic tall ship, the Norwegian three-masted barque Statsraad Lehmkuhl, is particularly stunning. The floating Elbe stage in front of the Landungsbrücken is THE artistic anchor of the HAMBURG PORT ANNIVERSARY: Elbe in Concert presents visitors with rousing live music and impressive performances, creating a unique atmosphere against the backdrop of the harbour skyline at night. This year’s partner
fiskaltrust Launches Portugal’s only Certified Fiscalisation Middleware and CashBox10.3.2026 08:30:00 CET | Press release
Integration Partners and Commercial Partners can now access the Portuguese market through fiskaltrust's POS System API, covering full AT (Autoridade Tributária e Aduaneira) compliance.
WELEDA x Stella McCartney: Paris Fashion Week / Skin Food: 100 years of loving skin9.3.2026 13:53:38 CET | Press release
Arlesheim, 09th March 2026 During this season’s Paris Fashion Week, WELEDA is backstage at the Stella McCartney show ensuring radiant skin: make-up artists draw specifically on the trusted nurturing power of the WELEDA Skin Food range to prep and prime the runway models’ skin perfectly for make-up and create a natural glow.
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm5.3.2026 08:54:06 CET | Press release
Aachen, Germany & Yeoju, South Korea, 5 March 2026 – Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom